Glynn Jeremy, Song Howard, Hull Bryan, Withers Stanley, Gelow Jill, Mudd James, Starr Albert, Wampler Richard
Biomedical Engineering, OregonHeart, Inc., Roseville, CA, USA.
Cardiothoracic Surgery, Oregon Health & Science University, Portland, OR, USA.
Artif Organs. 2017 Oct;41(10):904-910. doi: 10.1111/aor.12959. Epub 2017 Jul 13.
Widespread use of heart transplantation is limited by the scarcity of donor organs. Total artificial heart (TAH) development has been pursued to address this shortage, especially to treat patients who require biventricular support. We have developed a novel TAH that utilizes a continuously spinning rotor that shuttles between two positions to provide pulsatile, alternating blood flow to the systemic and pulmonary circulations without artificial valves. Flow rates and pressures generated by the TAH are controlled by adjusting rotor speed, cycle frequency, and the proportion of each cycle spent pumping to either circulation. To validate the design, a TAH prototype was placed in a mock circulatory loop that simulates vascular resistance, pressure, and compliance in normal and pathophysiologic conditions. At a systemic blood pressure of 120/80 mm Hg, nominal TAH output was 7.4 L/min with instantaneous flows reaching 17 L/min. Pulmonary artery, and left and right atrial pressures were all maintained within normal ranges. To simulate implant into a patient with severe pulmonary hypertension, the pulmonary vascular resistance of the mock loop was increased to 7.5 Wood units. By increasing pump speed to the pulmonary circulation, cardiac output could be maintained at 7.4 L/min as mean pulmonary artery pressure increased to 56 mm Hg while systemic blood pressures remained normal. This in vitro testing of a novel, shuttling TAH demonstrated that cardiac output could be maintained across a range of pathophysiologic conditions including pulmonary hypertension. These experiments serve as a proof-of-concept for the design, which has proceeded to in vivo testing.
心脏移植的广泛应用受到供体器官稀缺的限制。人们一直在研发全人工心脏(TAH)来解决这一短缺问题,尤其是用于治疗需要双心室支持的患者。我们开发了一种新型TAH,它利用一个连续旋转的转子,该转子在两个位置之间穿梭,以在没有人工瓣膜的情况下为体循环和肺循环提供搏动性、交替性血流。TAH产生的流速和压力通过调节转子速度、循环频率以及每个循环中向任一循环泵血所花费的比例来控制。为了验证该设计,将一个TAH原型置于一个模拟循环回路中,该回路模拟正常和病理生理条件下的血管阻力、压力和顺应性。在体循环血压为120/80 mmHg时,TAH的标称输出为7.4 L/min,瞬时流速达到17 L/min。肺动脉压以及左、右心房压均维持在正常范围内。为了模拟植入患有严重肺动脉高压的患者体内,将模拟回路的肺血管阻力增加到7.5伍德单位。通过提高向肺循环的泵速,随着平均肺动脉压升高至56 mmHg,心输出量可维持在7.4 L/min,而体循环血压保持正常。这种对新型穿梭式TAH的体外测试表明,在包括肺动脉高压在内的一系列病理生理条件下都可以维持心输出量。这些实验为该设计提供了概念验证,该设计已进入体内测试阶段。